bladder cancer

AZ withdraws Imfinzi in US bladder cancer use after trial failure
AZ withdraws Imfinzi in US bladder cancer use after trial failure
Pharmaforum
AstraZeneca
Imfinzi
bladder cancer
metastatic bladder cancer
clinical trials
Flag link:
Asco-GU – confirmatory Padcev trial throws a curveball
Asco-GU – confirmatory Padcev trial throws a curveball
EP Vantage
Astellas
Seagen
Padcev
bladder cancer
ASCO-GU
Flag link:
Merck Plans New Facility to Triple Production of Life-Saving Bladder Cancer Drug
Merck Plans New Facility to Triple Production of Life-Saving Bladder Cancer Drug
BioSpace
Merck
bladder cancer
TICE BCG
drug manufacturing
Flag link:
Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer
Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer
Fierce Pharma
Bristol-Myers Squibb
Opdivo
bladder cancer
Flag link:
ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer
ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer
Fierce Pharma
Merck
ESMO
bladder cancer
metastatic bladder cancer
Keytruda
Flag link:
Seattle Genetics stays step ahead of rivals with bladder cancer data
Seattle Genetics stays step ahead of rivals with bladder cancer data
BioPharma Dive
Seattle Genetics
Astellas
Padcev
bladder cancer
clinical trials
ESMO
Flag link:
AZ aims to cut cancer clinic visits with new Imfinzi regimen
AZ aims to cut cancer clinic visits with new Imfinzi regimen
Pharmaforum
AstraZeneca
lung cancer
bladder cancer
Imfinizi
dosing
Flag link:
Merck & Co’s Keytruda fails in first line bladder cancer
Merck & Co’s Keytruda fails in first line bladder cancer
Pharmaforum
Merck
Keytruda
bladder cancer
Flag link:
ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer
ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer
Fierce Pharma
Pfizer
Merck KGaA
Bavencio
ASCO 2020
bladder cancer
gestational trophoblastic tumors
clinical trials
Flag link:
Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water
Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water
Fierce Pharma
Seattle Genetics
Padcev
bladder cancer
Flag link:
Seattle could waltz in where Astra failed
Seattle could waltz in where Astra failed
EP Vantage
AstraZeneca
Imfinizi
bladder cancer
Seattle Genetics
clinical trials
Padcev
Flag link:
Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes
Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes
Fierce Pharma
Astellas
Seattle Genetics
Padcev
advanced bladder cancer
bladder cancer
Flag link:
Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response
Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response
Reuters
Seattle Genetics
Astellas
bladder cancer
Padcev
Flag link:
Roche's Tecentriq fails trial in form of urothelial cancer
Roche's Tecentriq fails trial in form of urothelial cancer
Reuters
Roche
Genentech
clinical trials
Tecentriq
urothelial cancer
bladder cancer
Flag link:
Merck's Blockbuster Drug Wins Key New FDA Approval
Merck's Blockbuster Drug Wins Key New FDA Approval
Motley Fool
Merck
Keytruda
bladder cancer
NMIBC
Flag link:
Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores
Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores
Endpoints
Merck KGaA
Pfizer
Bavencio
bladder cancer
FDA
Flag link:
Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK
Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK
Fierce Pharma
Merck
Keytruda
FDA
bladder cancer
NMIBC
Flag link:
FerGene’s Bladder Cancer Phase III Trial Hits Its Mark
FerGene’s Bladder Cancer Phase III Trial Hits Its Mark
BioSpace
FerGene
gene therapy
bladder cancer
NMIBC
Ferring Pharmaceuticals
Blackstone Life Sciences
clinical trials
Flag link:
Merck’s Keytruda gets FDA priority review for high-risk NMIBC
Merck’s Keytruda gets FDA priority review for high-risk NMIBC
Pharmaceutical Business Review
Merck
Keytruda
bladder cancer
priority review
NMIBC
FDA
Flag link:
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
Fierce Biotech
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
ESMO
urothelial cancer
Flag link:

Pages